Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPAN: Propranolol and Cyclophosphamide in Angiosarcoma
NCT02732678Phase 2Unknown
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- May 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of propranolol in angiosarcoma (3 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoints: Toxicity of each tested propranolol dose level in association to cyclophosphamide at 1 month and Non-progression rate at 3 months. Status: unknown.
02
Drugs
propranolol
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on NCT02732678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02732678.